Taljat David / Shutterstock.com
23 May 2023Big PharmaSarah Speight
Novartis ‘abused’ discovery process for Zolgensma patent
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
18 April 2023 Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Editor's picks
Editor's picks
Americas
18 April 2023 Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Americas
18 April 2023 Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.